Table 5.

Additional clinical trials on ClinicalTrials.gov involving iCasp9 T cell addback following haploidentical HSCT^*.

Registration ID	Underlying disease	Study protocol	Study cohort	Study Locations	Posted Date/status	Comment
NCT03301168	Malignant and non-malignant diseases	Phase II, T cell add-back after TCR αβ, and B cell deplete stem cell transplant	Children	Multiple locations, USA	Oct-4-2017 Active/not recruiting
NCT01744223	Malignant diseases	Phase I/II, T cell add-back after T cell deplete transplant	Adults	Multiple locations, USA	Dec-6-2012 Active/not recruiting
NCT02477878; EudraCT:2015-005176-17	Malignant diseases	Phase I, treatment of relapse or minimal residual disease after allogeneic HSCT	Adults	Multiple locations, USA & Italy	Jun-23-2015 Active/not recruiting	This study includes matched related and haploidentical HSCT
NCT03459170	Malignant diseases	Phase I, treatment of relapse or minimal residual disease after allogeneic HSCT	Children	Italy	Mar-8-2018 Recruiting	This study includes matched related and haploidentical HSCT
NCT03639844	Non-malignant diseases	T cell add-back after TCR αβ and B cell deplete transplant	Children and young adults	Multiple locations, USA	Aug-21-2018	Expanded access protocol
NCT03699475	Malignant diseases	Phase II/III, TCR αβ and B cell deplete transplant with iCasp9 T cell addback vs. Haploidentical HSCT with PTCy	Children and adults	Nashville, TN and San Antonio, TX	Oct-8-2018/Recruiting
NCT02231710	Non-malignant diseases	Phase I, T cell add-back after T cell deplete transplant	Children and adults	Seattle, WA	Sep-4-2014 Active/not recruiting	Closed after enrolling one patient

^*Excludes studies listed on Table 4.